Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Sanofi SA (SNY) vs Twilio Inc (TWLO) Price & Performance

Twilio IncTrade

Price performance (Past 24H)

Key statistics

Sanofi SA vs Twilio Inc — how do they compare? Sanofi SA trades at $40.04 (market cap $95.18B), while Twilio Inc trades at $289.41 (market cap $42.35B). The key difference: Sanofi SA is far larger — about 2.2× Twilio Inc's market cap, and Sanofi SA pays a 6.01% dividend while Twilio Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and Twilio Inc for 56 Days on average.

SNYTWLO
Market Cap
$95.18B$42.35B
Volume
2,995,6461,862,642
Sector
HealthTechnology
52-Week High
$52.34$301.27
52-Week Low
$39.51$106.23
Typical Hold Time
94 Days56 Days
Enterprise Value
$114.48B$40.76B
Dividend Yield
6.01%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Sanofi SA

Sanofi (SNY) trades at $40.07, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.21 exceeding the $1.10 estimate. Revenue for 2025 reached $46.72 billion, with a net income margin of 16.72%. Recent news highlights a significant $8 billion immunology alliance expansion with Regeneron, signaling strategic growth initiatives.

The outlook is mixed; solid profitability and a strategic partnership provide upside potential, but a projected net income decline to $4.0 billion in 2026 and bearish technical indicators pose risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, though investors should monitor execution of new collaborations and patent expiration impacts.

Twilio Inc

Twilio (TWLO) trades at $289.47, up 6.03% in the last 24 hours, with a bullish technical signal from moving averages. The stock is set to join the S&P 500 on October 6, 2026, a positive catalyst. Recent quarters show consistent earnings beats, with Q2 2026 EPS of $1.47 beating the $1.32 estimate. Revenue growth is accelerating, reaching $5.07 billion in 2025, with a net income margin turning positive at 0.66% after prior losses.

Outlook is positive due to S&P 500 inclusion and strong earnings momentum, but valuation remains elevated with a P/E of 38.09. Risks include competitive pressures and potential overvaluation concerns highlighted by HSBC's recent downgrade. Analyst consensus is bullish with 76.9% buy ratings, though the consensus price target of $254.65 suggests limited near-term upside from current levels.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

SNY
35% Buy65% Sell
Avg holding period · 94 Days
TWLO
100% Buy0% Sell
Avg holding period · 56 Days

Top news

Latest headlines on both assets

About Sanofi SA

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Read more on SNY →

About Twilio Inc

Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.

Read more on TWLO →